4
Changes in Ownership
Rapport Therapeutics, Inc. Filed Acc 0001193125-25-241475
Chief Scientific Officer sold 8,500 shares at an average $25.79 ($219,196)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Bredt David Chief Scientific Officer | 2025-10-15 | Sale 10b5-1 | −7,418 | $25.73 | $190,887 | 410,724 | D |
| Bredt David Chief Scientific Officer | 2025-10-15 | Sale 10b5-1 | −1,082 | $26.16 | $28,310 | 409,642 | D |
| Open-market sales · 8,500 sh · avg $25.79 · $219,196 | |||||||
Loading xslF345X05/ownership.xml…